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        T lymphocytes respond to antigenic peptides 
presented on major MHC molecules. Cyto-
toxic CD8     T cells recognize peptides in the 
context of MHC class I, whereas CD4     Th 
cells recognize peptides in complex with MHC 
class II. Naive T cell activation is restricted to 
secondary lymphoid organs, such as the spleen 
and LNs, and is thought to rely on specialized 
  “  professional  ”   APCs comprising B cells, macro-
phages, and DCs. The APC composition of 
lymphoid organs likely encodes a potential to 
initiate distinct T cell responses. However, the 
diff  erential contribution of APC to in vivo im-
mune responses remains poorly understood. 
  Natural IFN-producing cells (IPCs) are a 
unique subset of hematopoetic cells that play a 
critical role in the innate and adaptive immune 
defense against infections (  1  ). Viruses (or un-
methylated CpG DNA) engage Toll-like re-
ceptor (TLR) 7 and 9 on IPCs (  2  ) and trigger 
the secretion of massive amounts of type I in-
terferons (IFN-    , -    , -    , and -    ) (  3  ). This spe-
cialization of IPCs in cytokine production is 
refl  ected in their distinct   “  plasmacytoid  ”   mor-
phology, resembling Ig-secreting plasma cells (  4  ). 
IPC-derived cytokines are critical for the 
initiation of early antiviral NK cell responses 
(  5, 6  ). In addition, IPC-derived type I IFNs 
boost the ability of conventional DCs (cDCs) 
to mature and stimulate T cells, thus, promot-
ing antiviral CTL responses (  7, 8  ). Further-
more, IPCs provide a critical costimulatory 
signal for the CpG-induced activation of cDCs 
(  9, 10  ). Independent of their cytokine- and 
CD40L-mediated accessory function to con-
trol NK and cDC activities, IPCs have also 
been proposed to play a direct role as APCs in 
the onset of T cell stimulation. The constitutive 
presence of IPCs in lymphoid organs, their ex-
pression of MHC molecules, and their acquisi-
tion of DC morphology upon culture, has led 
to the idea that IPCs represent a distinct DC 
subset, the so-called plasmacytoid DCs (PDCs). 
However, the original discovery of DCs de-
fi  ned them by the capacity to prime naive T cells 
(  11  ), and this activity has remained their hall-
mark. Moreover, recent in vivo DC depletion 
experiments indicate that CD11c  high   cDCs are 
required to initiate cytotoxic CD8     T cell re-
sponses against intracellular pathogens (  12, 13  ). 
The potential of IPC/PDCs to prime naive 
T cells, however, remains controversial. Freshly 
isolated PDCs are generally poor T cell stimu-
lators. Thus, human blood  –  derived PDCs do 
not stimulate naive CD4  +   T cells in a MLR, 
unless cultured in the presence of IL-3 or virus 
(HSV) (  14  ). Moreover, murine splenic PDCs 
fail to induce naive T cell proliferation to en-
dogenous antigens, even after virus exposure 
(  15  ). In contrast, murine peptide-pulsed PDCs 
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derived from Flt-3  –  driven BM culture or spleens can promote 
the in vitro expansion of CD4     T cells and Th cell polariza-
tion (  16  ). Adoptive transfer experiments with splenic and BM 
culture  –  derived, CpG-matured PDCs showed that PDCs can 
elicit responses of naive CD8     T cells to endogenous, but not 
exogenous, antigens (  17  ). These confl  icting results are likely 
caused by the diff  erent source of the PDCs used in the reports. 
Moreover, none of the studies addressed the in vivo potential 
of unmanipulated PDCs to prime naive T cells. 
  Recently, IPC/PDCs have been shown to play a critical 
role in the control of airway infl  ammation (  18, 19  ) and allo-
transplant rejection (  20, 21  ). Although these fi  ndings mark 
PDCs as potential candidates for future adoptive cell thera-
pies, such approaches will require better understanding of the 
in vivo characteristics of this unique cell type. 
  We analyze CD4     and CD8     T cell responses to antigen 
challenge in mice that were conditionally depleted of CD11c  high   
cDCs, but retain IPC/PDCs. We show that depletion of cDCs 
impairs splenic T cell responses, indicating that PDCs are in-
capable of T cell priming in this organ. In contrast, the combined 
use of cDC ablation and a novel PDC-specifi  c antigen-targeting 
strategy revealed that, in LNs, PDCs can effi   ciently trigger 
productive naive CD4     T cell responses. Interestingly, and in 
contrast to cDC-driven responses, the PDC-triggered CD4     
T cell stimulations lack a concomitant CD8     T cell expansion. 
Our in vivo results, thus, characterize PDCs as bona fi  de DCs 
that can initiate unique CD4     Th cell  –  dominated primary 
immune responses. 
    RESULTS   
  PDCs are spared from ablation in DTx-treated CD11c-DTR 
transgenic mice 
  To investigate diff  erential in vivo functions of APCs in lym-
phoid organs, we recently developed a diphtheria toxin re-
ceptor (DTR)  –  based system that allows the conditional ablation 
of CD11c  high   cDCs (  12  ). DTR expression in CD11c-DTR 
transgenic mice is driven by a DNA fragment fl  anking the 
  Figure 1.     PDCs are spared from ablation in DTx-treated CD11c-
DTR transgenic mice. (A) Flow cytometric analysis of the spleens of 
untreated controls and CD11c-DTR transgenic mice 1 d after i.v. injec-
tion of DTx (4 ng/body weight). cDCs are gated as CD11c  high   mPDCA-
1  neg   cells; PDCs are defi  ned as being CD11c  int   mPDCA-1   . (left) Dot 
blots show cells gated according to scatter. (right) The bar graph repre-
sents analysis of splenic cDCs and PDCs of untreated mice and mice 24 h 
after treatment (i.p. DTx; 10     g OVA i.v.).   n   = 5 for each group. (B) DTR/
GFP expression profi  les of splenic cDCs and PDCs isolated from CD11c-
DTRtg mice that were untreated or treated with DTx. Cells are defi  ned 
and gated as in A. Graphs are representative of fi  ve repeats. Percentage 
refers to DTx-sensitive GFP     mPDCA-1    CD11c low   cells (filled area). 
(C) Flow cytometric analysis of popliteal LNs of control mice CD11c-DTR 
transgenic mice 1 d after s.c. injection of 20 ng DTx into the hind foot-
pads. (left) Dot blots show cells gated according to scatter. (right) Histo-
gram represents analysis of splenic cDCs and PDCs of untreated mice 
and mice 24 h after the indicated treatment (i.p. DTx; 10     g OVA i.v.). 
  n   = 5 for each group. (D) DTR-GFP expression profiles of LN PDCs iso-
lated from untreated or treated CD11c-DTRtg mice. Note absence of 
GFP     mPDCA-1    CD11c low   subpopulation observed in spleen (B). 
(E) IFN-     production by splenic PDC and non-PDC cell fractions isolated 
from noninjected or DTx-injected CD11c-DTRtg mice and incubated in 
vitro for 20 h in the presence or absence of 400 HAU/ml influenza 
virus and blood sera analysis of DTx-treated and untreated CD11c-
DTRtg mice, 6 h after PBS or 100     g CpG i.v. injection. Error bars 
depict the SD.     JEM VOL. 204, August 6, 2007 
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mice a small fraction of mPDCA-1     440c     CD11c  low   cells 
that were DTR/GFP     and DTx sensitive; however, upon 
in vitro exposure to virus, these cells did not secrete IFN-     
(  Fig. 1, B and D  , and not depicted). Collectively, these results 
indicate that PDCs of CD11c-DTR transgenic mice are resis-
tant to DTx treatment. CD11c-DTR transgenic mice, thus, 
provide a unique model to study the role of PDCs in the 
priming of immune responses in the absence of conventional 
CD11c  high   DCs. 
  PDCs fail to prime naive T cells in the spleen 
  We fi  rst investigated the potential of splenic PDCs to stimulate 
naive T cells in the absence of CD11c  high   cDCs. We isolated 
TCR transgenic OVA-specifi  c CD8     and CD4     T cells from 
OT-I and -II mice, respectively (  34, 35  ). Donor mice carried 
an allotypic marker (CD45.1) that allowed for detection of the 
transferred cells in the recipient mice. Before transfer, the 
T cells were labeled with the intracellular dye CFSE, which 
allows the monitoring of in vivo proliferation (  36  ). T cells were 
cotransferred into WT and CD11c-DTR transgenic C57BL/6 
mice. The grafted mice were treated with DTx and, 8 h later, 
immunized by i.v. injection of soluble OVA (10     g) or OVA-
loaded splenocytes (  37  ). 4 d after immunization, the mice were 
killed and spleens were isolated and analyzed for the prolifera-
tion status of the T cell grafts (  Fig. 2  ).   All challenges resulted in 
vigorous expansion of both CD4     and CD8     T cell grafts in 
the WT recipient mice. As previously reported (  12  ), depletion 
of CD11c  high   cDCs impaired the response of CD8     T cells to 
cell-associated antigen. Presentation of antigen in the context 
of MHC class I to CD8     T cells requires a unique phagosome-
to-cytosol pathway resulting in cross-presentation, which is 
an activity proposed to be uniquely associated with cDCs or 
cDC subsets (  12, 37, 38  ). In support of this notion, we found 
that cDCs are also needed for CD8     T cell priming after chal-
lenge with exogenous soluble antigen (  Fig. 2  ). Moreover, de-
pletion of splenic cDCs also abrogated OVA-specifi  c CD4     
T cell responses to cell-associated and soluble antigen, thus 
extending the study by Tian et al. (  39  ). Importantly, as opposed 
to a recent study (  40  ), we evaluated the T cell  –  priming poten-
tial of PDCs in the absence of cDCs. Splenic PDCs are un-
able to prime naive CD4     and CD8     T cells in the absence 
of CD11c  high   cDCs. 
  PDCs can prime naive CD4     T cells in LNs, but fail 
to support CD8     T cell priming 
  T cell responses are initiated in specialized secondary lymphoid 
organs, such as the spleen and LNs, which diff  er considerably 
in their microarchitecture, refl  ecting their specialization for the 
handling of blood- and tissue-borne antigens, respectively. We 
next investigated whether CD11c  high   DCs would also be re-
quired in the LNs. Local, s.c. DTx injection results in the rapid 
depletion of LN-resident cells expressing the DTR-GFP fu-
sion protein, including both CD8         and CD8        –    CD11c  high   
cDCs and sinusoidal macrophages (  23  ), but not PDCs (  Fig. 1 C  ; 
  Fig. 3 A  ; Fig. S1, A  –  C).   Repetitive s.c. DTx injection results 
in persistent cDC ablation (  Fig. 3 A   and Fig. S2 A, available at 
  Itgax   gene (  22  ), which encodes the       X   subunit of the CD11c 
integrin. Murine CD11c expression is found in all cDCs, but 
has also been reported for certain macrophages (  23  –  25  ), acti-
vated T cells (  26  ), NK cells (  27  ), and plasmablasts (  28  ). 
  Murine PDCs are defi   ned as being CD11c  low   B220     
Ly6C    , and, furthermore, can be identifi  ed by the PDC-
specifi  c antibodies 120G8 (  29  ), 440c (  30  ), and mPDCA-1 (  31  ). 
To test the DTx sensitivity of CD11c-DTR transgenic 
CD11c  low   PDCs, we injected CD11c-DTR transgenic C57BL/6 
mice with DTx. Flow cytometric analysis of the spleens 1 d 
after DTx treatment revealed that PDCs were spared from 
DTx-induced ablation, whereas cDCs were depleted (  Fig. 1 A   
and Fig. S1 A, available at http://www.jem.org/cgi/content/
full/jem.20062373/DC1).   The DTx resistance of PDCs 
is explained by the absence of expression of the DTR-GFP 
fusion protein by the bulk population of these cells (  Fig. 1 B  ). 
Moreover, it was also confi  rmed for LN PDCs (  Fig. 1, C and D  ; 
  Fig. 3 A  ; Fig. S1 A) and PDCs located in the bone marrow 
(Fig. S1 A). This indicates that the 5.5-kb   Itgax   promoter/en-
hancer fragment (  22  ) does not carry all transcription control 
elements required for physiological       X   subunit expression 
in CD11c     cells (  32  ), and further supports the notion that 
PDCs and cDCs are genetically distinct entities (  33  ). To in-
vestigate whether the toxin treatment results in a functional 
impairment of PDCs, we tested type I interferon responses. 
As seen in   Fig. 1 E  , DTx treatment neither aff  ected the 
IFN-     response to in vivo CpG treatment nor compromised 
the ability of PDCs to produce IFN-     in response to an in vitro 
infl  uenza virus challenge. Notably, we consistently observed 
in spleens, but not LNs, of CD11c-DTR transgenic C57BL/6 
  Figure 2.     cDC ablation impairs splenic CD4     and CD8     T cell 
priming. Flow cytometric analysis of cotransferred CFSE-labeled CD45.1    
OT-I and -II T cell grafts (10  6   cells each) in DTx-treated nontransgenic and 
CD11c-DTR transgenic mice (CD45.2) 4 d after i.v. immunization with 
OVA-loaded splenocytes or soluble OVA. Histograms represent cells gated 
according to scatter, CD45.1, and CD8 or CD4 surface expression, as indi-
cated in the dot plots. Data show results of one representative experiment 
out of three.     1926 LN PDC PRIME CD4 T CELLS | Sapoznikov et al.
OVA (  Fig. 3 B  ). Importantly, the DTx-induced cDC deple-
tion abrogated the expansion of CD8     T cells, indicating 
that, as in the spleen, priming of naive CD8     T cells required 
the presence of cDCs. Surprisingly, however, we observed a 
proliferative response of the grafted CD4     T cells in the 
cDC-depleted LNs (  Fig. 3 B  ). Importantly, this was unlikely 
to be caused by residual cDCs because the DTx treatment 
impaired in the same LNs the CD8     T cell response, which 
is generally more sensitive to antigen challenge (  41  ). The 
persistence of the CD4     T cell priming in the absence of 
cDCs was also observed in CD11c-DTRtg BALB/c mice, in 
combination with an OVA-specifi  c TCR transgenic naive 
CD4     T cell graft isolated from DO11.10 mice (Fig. S3) 
(  42  ). Moreover, to confi  rm our observation in a non-TCR 
transgenic system and with an antigen other than OVA, we 
challenged untreated and cDC-depleted DTRtg mice with 
KLH/CpG and analyzed the resulting response of endoge-
nous CD4     T cells. 7 d after s.c. antigen challenge, we puri-
fi  ed CD4     T cells from popliteal LNs and subjected them to 
an in vitro restimulation protocol with KLH-pulsed APC. 
Again, CD4     T cells were effi   ciently primed irrespective of 
the presence of cDCs (Fig. S2). 
  Our data show that LNs contain APCs other than CD11c  high   
DCs or macrophages that are capable of stimulating naive 
CD4     T cells. Although PDCs are potential candidates, other 
MHC class II     cells could be responsible for the CD4     T cell 
priming. By far, the largest MHC class II     population in the 
LNs are B lymphocytes, which, even when naive, have been 
shown to effi   ciently ingest and process noncognate protein 
antigens (  43  ). However, the ability of B cells to activate naive 
CD4     T cells remains under debate (  44  –  46  ). Moreover, 
pMHC encounter on B cells is believed to result in non-
productive T cell priming or tolerization (  47  ). To investigate 
the role of B cells in our system, we crossed the CD11c-
DTR transgene onto a B cell  –  defi  cient genetic background 
(C57BL/10-  Igh-6tm1Cgn   [    MT]) (  48  ). CD11c-DTRtg:    MT 
and     MT C57BL/6 mice were engrafted with OVA-specifi  c 
http://www.jem.org/cgi/content/full/jem.20062373/DC1). 
To investigate the impact of the LN cDC depletion on T cell 
responses in this organ, we engrafted WT and CD11c-DTR 
transgenic C57BL/6 recipient mice with a mixture of OVA-
specifi  c CD4     (OT-II) and CD8     T cells (OT-I). The mice 
were subjected to the DTx treatment (which was continued 
throughout the experiment to maintain cDC depletion;   Fig. 
3 A  ) and, 8 h later, immunized by s.c. injection of 10     g OVA. 
3 d after immunization, we isolated the antigen-draining pop-
liteal LNs and analyzed them for the proliferation status of 
grafted T cells. The adoptively cotransferred CD45.1     CD4     
and CD8     T cells readily proliferated in the LNs of DTx-
treated WT mice in response to immunization with soluble 
  Figure 4.     In vivo antigen acquisition by PDCs. Flow cytometric anal-
ysis of popliteal LNs harvested 24 h after s.c. injection of DQ-OVA into 
hind footpads. Histograms represent analysis of DQ-OVA uptake by cDCs 
(CD11c  high   mPDCA-1      ), PDCs (CD11c  int   mPDCA-1   ), and B cells (CD11c       
B220    ). Results are representative of two independent experiments.     
  Figure 3.     Ablation of cDCs impairs CD8     T cell priming, but not 
CD4     T cell priming, in the LNs. (A) Flow cytometric analysis of the 
popliteal LNs of CD11c-DTR transgenic mice during the course of a prim-
ing experiment. Mice were injected twice with DTx in the hind footpads, 
on day 1 and 3. The line graph represents the analysis of LN cDCs and 
PDCs as indicated in the FACS blots (top right).   n   = 3 for each group. The 
bottom diagram refers to T cell priming experiments performed in B. 
(B) Flow cytometric analysis of cotransferred CFSE-labeled CD45.1+ OT-I 
and -II cells (bottom row, OT-II transfer only) into DTx-treated nontransgenic 
and CD11c-DTR transgenic mice (CD45.2+) 4 d after s.c. immunization 
with soluble OVA. Histograms represent cells gated according to scatter, 
CD45.1, and CD8 or CD4 expression, as indicated in the dot plots. Data 
show results of 2 representative experiments out of 10 repeats. Graph 
summarizes percentages of dividing CFSE-labeled CD45.1     OT-II cells in 
mice (  n   = 14) that were treated with DTx and immunized, compared with 
proliferation in immunized WT control mice (  n   = 8; set as 100%). Each dot 
represents an independent mouse.     JEM VOL. 204, August 6, 2007 
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(Fig. S4 C). Collectively, these data suggest that cells other 
than cDCs, macrophages, B cells, or LCs are responsible for 
the priming of CD4     T cells, and point at a role for PDCs 
in antigen presentation. 
  LN PDCs effi  ciently acquire and process soluble antigen 
and prime productive T cell responses 
  Antigen presentation and CD4     T cell priming by LN-
resident PDCs would require their antigen uptake. Impor-
tantly, soluble antigens of low molecular weight (  <  70 kD) are 
readily transported into the T cell zone of the LN, i.e., PDC 
proximity, via a highly developed conduit network (  51  ). To 
investigate whether LN PDCs have access to antigen, we 
immunized C57BL/6 WT mice with DQ-OVA and analyzed 
LN APC populations for antigen uptake. This fl  uorogenic 
reagent is undetectable in its unprocessed form because of 
autoquenching, but becomes fl  uorescent upon entry into 
acidic, endosomal cellular compartment. As seen in   Fig. 4  , 
DQ-OVA was readily ingested by the LN-resident CD11c  high   
DCs and subjected to processing as indicated by the induc-
tion of the green fl  uorescent label.   PDCs were labeled at least 
as effi   ciently as CD11c  high   cDCs, whereas B cells remained 
CD4     T cells (OT-II) and subjected to the DTx treatment 
and OVA immunization. B cell defi  ciency resulted in a re-
duced recovery of grafted CD4     T cells in DTx-treated 
CD11c-DTRtg:    MT and     MT C57BL/6 mice. However, 
the frequency of OT-II cells that lost the CFSE-label, and 
thus proliferated in response to the OVA challenge, was un-
aff  ected by the absence of B cells (Fig. S4, A and B, available 
at http://www.jem.org/cgi/content/full/jem.20062373/DC1). 
CD4     T cell priming in the LNs, thus, persisted in the com-
bined cells in the absence of B cells and CD11c  high   cDCs. 
Other potential APC candidates are epidermal Langerhans 
cells (LCs), which are CD11c  neg  , but up-regulate CD11c 
expression upon migration to the skin-draining LNs (  49  ). 
LCs would, hence, be expected to become DTx sensitive by 
the time they reach the LNs. To nevertheless exclude the 
possibility that the CD4     T cell response we observed was 
caused by residual LCs, we crossed the CD11c-DTR trans-
genic mice to mice that harbor the DTR gene under the LC-
specifi  c Langerin promoter (  50  ). DTx-treatment of LanDTR:
CD11cDTR mice results in ablation of cDCs and LCs (un-
published data). However, the response of the adoptively trans-
ferred OT-II CD4     T cells to the OVA challenge persisted 
  Figure 5.     CD4     T cells that are primed in the absence of cDCs differentiate into Th cells with memory phenotype and persist for extended 
periods of time. (A) CFSE-labeled CD45.1     OT-II cells were transferred into nontransgenic and CD11c-DTR transgenic mice (CD45.2    ). 1 d later, mice 
were treated s.c. with DTx; 8 h later, they were immunized in their hind footpads with OVA and CpG. 3 d after immunization, IFN-  	   production in the 
popliteal LN was assessed after in vivo restimulation with OVA peptide, 2 h before removal of popliteal LNs. Data represent IFN-  	   profi  les after gating on 
CD4     CD45.1    lymphocytes. Results are representative of two independent experiments. (B) CFSE-labeled CD45.1     OT-II cells were transferred into mixed 
[WT   >   WT] or [DTRtg   >   WT] BM chimeras (CD45.2    ). The mice were injected s.c. with DTx 1 d after the transfer, and they were immunized 8 h later with 
OVA injected into their hind footpads. Sequential s.c. DTx injections were performed every second day until day 21. Blood was collected on day 4, 11, and 
21 and evaluated for the presence of OT-II cells (CD4     CD45.1   ) and expression of the memory T cell marker CD45RB. Bar graph depicts mean fl  uores-
cence intensity values of blood staining for CD45RB on day 4, 11, and 21. Results are representative of two independent experiments.   1928 LN PDC PRIME CD4 T CELLS | Sapoznikov et al.
  PDC-specifi  c antigen targeting and PDC-mediated in vivo 
and in vitro CD4     T cell priming 
  The aforementioned results suggest that LN PDCs effi   ciently 
ingest exogenous antigen and are able to initiate productive 
CD4     T cell responses. To obtain independent evidence that 
PDCs can act as APCs, we decided to adopt a strategy involv-
ing specifi  c, antibody-mediated, antigen-targeting APCs (  53  ) 
and conjugate the PDC-specifi  c mPDCA-1 antibody to OVA. 
To avoid complement-dependent lysis (  31  ), we used a nonde-
pleting F(ab  ’  )  2   fragment. Functional integrity of the construct 
was tested by Western blotting. As depicted in   Fig. 6 A  , the 
conjugates were readily detected both via the kappa light chain 
and the OVA-fraction, whereas free OVA or unconjugated 
mPDCA-1  –  F(ab  ’  )  2   fragments were only detected with the 
anti-rat IgG or the -OVA antibody, respectively.   The OVA-
conjugated antibody fragment specifi   cally targeted PDC in 
splenic or LN single-cell suspensions in vitro (unpublished 
data). To demonstrate in vivo specifi  city, we took advantage of 
a FITC conjugate of the mPDCA-1  –  F(ab  ’  )  2  -OVA construct. 
Intravenous or s.c. injection of FITC  –  mPDCA-1  –  F(ab  ’  )  2    –
  OVA resulted in specifi  c labeling of CD11c  low   PDCs in spleens 
and LNs and spared CD11c  high   cDCs (  Fig. 6 B  ). 
  To direct the OVA antigen to both PDCs and cDCs, 
we used the mPDCA-1  –  F(ab  ’  )  2    –  OVA conjugate (mPDCA-
1  –  OVA) and an OVA conjugate that targets a subset of 
CD11c  high   cDCs via the CD205 receptor (DEC205  –  OVA) 
(  53, 59  ). We fi  rst investigated the response of OVA-specifi  c 
CD8     T cells (OT-I) to the conjugate challenge. As seen in 
  Fig. 7 A  , s.c. immunization of untreated CD11c-DTRtg mice 
with the mPDCA-1  –  OVA and DEC205  –  OVA conjugates 
resulted in comparable responses of the naive CD8     T cells in 
the draining popliteal LNs.   Importantly, depletion of cDCs 
abrogated both the DEC205  –  OVA and the mPDCA-1  –
  OVA  –  induced CD8     T cell expansion. Thus, the cDC-driven 
unaff  ected by the DQ-OVA challenge. Importantly, as it 
occurred in naive mice, antigen uptake was independent of 
anti-OVA antibodies, and hence Fc  	   receptors, which have 
been implied in PDC antigen capture (  52  ). Thus, PDCs have 
access to antigen in our experimental system, and they could 
be responsible for the priming of CD4     T cells in LNs de-
pleted of the CD11c  high   DCs. 
  Proliferative T cell expansion can be associated with the 
generation of cytokine-producing eff  ector T cells, but also 
abortive T cell responses (  53  –  55  ). We therefore investigated 
the quality of the primed LN CD4     T cells by studying Th 
cell polarization and long-term T cell survival. To analyze Th 
cell polarization of the grafted OVA-specifi  c CD4     T cells, 
we performed an in vivo restimulation assay by rechallenging 
the OVA-immunized mice with an i.v. injection of OVA 
peptide (  56  ). Both in the presence and absence of CD11c  high   
cDC, CD4     T cells diff  erentiated effi   ciently into IFN-  	    –
  producing eff  ector T cells (  Fig. 5 A  ).   Abortive T cell stimula-
tion is characterized by a collapse of the antigen-specifi  c 
T cell population after its initial expansion (  53, 54  ). To test 
the persistence of CD4     T cells that were primed in the ab-
sence of cDCs, we used mixed CD11c-DTR BM chimeras, 
which allow for repetitive DTx treatment, and hence extended 
cDC depletion (  57  ). In both untreated and cDC-depleted 
mice, the OT-II CD4     T cell graft clonally expanded and 
persisted well beyond the initial antigen challenge (  Fig. 5 B  ). 
Furthermore, in both the presence and absence of cDCs, 
the grafted naive CD4     T cells diff  erentiated into T cells 
of CD45RB  low   memory phenotype (  58  ). Collectively, PDCs 
seem capable of stimulating naive CD4     T cells, resulting in 
a persistent response that includes IFN-  	    –  producing eff  ector 
T cells of memory phenotype. Importantly, and in contrast to 
the immune reaction triggered by cDCs, this response is not 
accompanied by a concomitant CD8     T cell response. 
  Figure 6.     Characterization of selective APC targeting via the anti  –  mPDCA-1  –  F(ab  ’  )  2    –  OVA construct. (A) Western blot analysis of the OVA-
conjugated antibody construct. Free OVA and unconjugated or OVA-conjugated anti  –  mPDCA-1 antibody constructs were resolved by SDS-PAGE (4-12% 
gradient Tris-glycine gel) and, after immunoblotting, detected with anti  –  rat and anti-OVA antibody, respectively. Lanes 1 and 5 contain free OVA, lanes 
2 and 6 contain the unconjugated anti  –  mPDCA-1  –  F(ab  ’  )  2   antibody fragment, and lanes 3 and 4 and 7 and 8 contain two fractions of the anti  –  mPDCA-1  –
 F(ab ’ ) 2  – OVA  conjugate.  (B)  Specifi  c in vivo targeting of PDCs with FITC-labeled anti  –  mPDCA-1  –  F(ab  ’  )  2    –  OVA. Conjugates were injected i.v. or s.c. and, after 
3 h, spleens and popliteal and inguinal LNs were isolated. Counterstaining with CD11c was performed on single-cell preparations from untreated (left dot 
plots) or in vivo  –  targeted cells (middle and right dot plots). Note that the staining in the FL-1 channel is based on the in vivo – injected,  FITC-coupled 
mPDCA-1 – F(ab ’ ) 2  – OVA  construct.   JEM VOL. 204, August 6, 2007 
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naive CD4     and CD8     T cells in the spleen is uniquely re-
stricted to cDCs. Ablation of cDCs, however, revealed the sur-
prising potential of PDCs to support CD4     T cell responses 
CD8     T cell response to the mPDCA-1  –  OVA conjugate was 
likely caused by antibody-independent antigen uptake by 
cDCs or secondary cross-presentation of cellular PDC debris 
by cDCs. Conventional DC ablation revealed that, in contrast 
to a recent study (  40  ), even when directly targeted with exog-
enous antigen, PDCs seem unable to trigger CD8     T cell re-
sponses. Instead, our results support the notion of the general 
inability of PDCs to channel exogenous antigen into the 
MHC class I presentation pathway and cross-present (  17  ). 
  Next, we analyzed the response of OVA-specifi  c LN 
CD4     T cells (OT-II) to conjugate challenge. Like the im-
munization with OVA, challenge of untreated CD11c-DTRtg 
mice with the antibody-conjugates resulted in vigorous ex-
pansion of the CD4     T cell grafts. In contrast to the CD8     T 
cell responses, and confi  rming our previous results (  Fig. 3  ), the 
CD4     T cell responses to the OVA and mPDCA-1  –  F(ab  ’  )  2    –
  OVA challenge resisted the DTx treatment in CD11c-DTR 
transgenic mice (  Fig. 7 B  ). Importantly, however, the CD4     
T cell response to the DEC205  –  OVA challenge was impaired 
by depletion of CD11c  high   cDCs. These results provide further 
evidence that the CD4     T cell response we observe in the 
absence of CD11c  high   cDCs is driven by PDCs. Notably, the 
antibodies to DEC205 and mPDCA-1 target distinct surface 
receptors (  60, 61  ), which likely diff  er in their potential to pro-
mote endocytosis. This precludes any quantitative conclusion 
on the priming potential of cDCs versus PDCs. 
  To obtain fi  nal proof for the CD4     T cell priming poten-
tial of PDCs, we decided to use an antibody-mediated deple-
tion protocol to test T cell responses in the combined absence 
of both cDCs and PDCs. However, in our hands, even re-
petitive injection of mPDCA-1 and anti-Gr1 antibodies 
(  18, 31  ) resulted in incomplete LN PDC depletion (unpublished 
data). Therefore, we resorted to an in vivo loading/in vitro 
readout system. WT BALB/c mice were immunized with 
OVA or mPDCA-1  –  OVA. 1 d later, PDCs, cDCs, and B 
cells were isolated from LNs and spleens, sorted to purity, 
and tested in vitro for their ability to prime naive OVA-spe-
cifi  c CD4     T cells (DO11.10). As seen in   Fig. 8  , cDCs iso-
lated from LNs or spleens of OVA-immunized mice readily 
stimulated T cell proliferation, whereas cDCs and B cells iso-
lated from mPDCA-1  –  OVA  –   immunized mice failed to do 
so.   This confi  rms the specifi  city of the in vivo antigen-targeting 
strategy (  Fig. 6 B  ). Importantly, PDCs isolated from LNs of 
mice immunized with both OVA and mPDCA-1  –  OVA were 
able to stimulate the naive CD4     T cells. Substantiating our 
in vivo data on the inability of splenic PDCs to prime CD4     
T cells, in the in vitro assay PDCs isolated from spleens of im-
munized mice also failed to stimulate the T cells. Collectively, 
our results show that LN PDCs can initiate unique CD4     
Th cell  –  dominated primary immune responses. 
    DISCUSSION   
  We analyzed the responses of naive CD4     and CD8     T cells 
to antigen challenge in mice that were depleted of conven-
tional CD11c  high   cDCs, but retained PDCs. In support of 
previous reports (  12, 39  ), we found that the capacity to prime 
  Figure 7.     In vivo antigen targeting of PDCs leads to priming of LN 
CD4     T cells, but not CD8     T cells, in the absence of cDCs. (A) Flow 
cytometric analysis of transferred CFSE-labeled CD45.1     OT-I cells into 
s.c. DTx-treated CD11c-DTR transgenic mice (CD45.2) 4 d after footpad 
immunization with 8    g  mPDCA-1 – OVA  (OVA  content,     7.5%) or 7 ng 
DEC205  –  OVA (OVA content,     10%). Histograms represent CFSE profi  les 
of cells gated according to CD45.1 and CD8 expression, as indicated in the 
dot plot. Data show a representative result for three experiments. (B) Flow 
cytometric analysis of transferred CFSE-labeled CD45.1     OT-II cells into 
DTx-treated CD11c-DTR transgenic mice, 4 d after footpad immunization 
with F(ab)  2  , OVA, control F(ab)  2  – OVA,  mPDCA-1 – F(ab) 2  – OVA,  or  DEC20-
OVA. Histograms represent CFSE profi  les of cells gated according to 
CD45.1 and CD4 expression, as indicated in the dot plot. Data show one 
representative experiment out of three.     1930 LN PDC PRIME CD4 T CELLS | Sapoznikov et al.
  Surprisingly, PDCs could prime CD4     T cells in the 
LNs, but not in cDC-depleted spleens. It remains unclear 
whether this discrepancy results from the distinct organ ar-
chitecture or refl  ects an inherent diff  erence between splenic 
and LN PDCs. In support of the former, in naive mice PDCs 
are located in the red pulp and T cell area, but rarely in the 
marginal zone, which is the site of blood-borne antigen entry 
to the spleen (  62  ). Moreover, when challenged, splenic PDCs 
form clusters and, compared with cDCs, they show a delayed 
translocation to the T cell zone (  62  ). This migration might be 
critical for the spleen, whereas it may not be required in the 
LNs. Recruitment of PDCs to the LNs occurs via high en-
dothelial venules (HEVs), and thus the cells enter directly 
into the T cell area (  63  ). Even before antigen-carrying DCs 
arrive from the periphery, resident LN APCs are known to 
take up soluble antigens (  47  ), which enter the deeper LNs 
through an intricate network of conduits (  51  ). Accessibility 
of antigen to LN PDCs is also highlighted by the observation 
that these cells readily ingested injected DQ-OVA (  Fig. 4  ), 
although, interestingly, we failed to label splenic PDCs by 
intravenous DQ-OVA injection (not depicted). Alterna-
tively, the unique ability of LN PDCs to prime CD4     T cells 
might indicate that these cells diff  er from their splenic coun-
terpart. Indeed, even when we targeted antigen directly to 
both LN and spleen PDCs and overrode the need for trans-
location (by an in vitro readout;   Fig. 8  ), splenic PDCs failed 
to prime CD4     T cells (  Fig. 8  ). Interestingly, LN PDCs are 
characterized by a distinct expression pattern of activation 
markers, such as Sca-1, and are poor producers of IFN-     
compared with Sca-1     BM PDCs (unpublished data). How-
ever, a more detailed comparative study will be required to 
investigate qualitative diff  erences between splenic and LN 
PDCs. Importantly, the antigen challenge results in a rapid 
PDC infl  ux to the LN, and in our experimental setup, we do 
not discriminate between LN-resident and recruited PDCs. 
  Although we would like to stress that we do not want to 
compare the effi   ciency of cDCs and PDCs in T cell priming 
potential, we establish that PDCs can prime naive CD4     
T cells. Absence of cDCs is arguably an artifi  cial situation 
unlikely to occur under physiological circumstances. However, 
we predict that pathogens that specifi  cally target or acti-
vate PDCs will elicit exclusive CD4     T cell responses sup-
porting humoral, but not cytotoxic, immunity. PDC-specifi  c 
targeting could be mediated by endocytic receptors, such as 
Siglec-H (  40, 64  ), which are expressed on murine PDCs, 
but not cDCs. So far, murine PDC-specifi  c pathogen sen-
sors have not been reported, although PDCs are character-
ized by higher expression of TLR7 and TLR9 (  65  ), which 
are also expressed by human PDCs, but absent from human 
interstitial DCs (  2, 66  ). The unique priming of CD4    , but 
not CD8    , T cell responses by PDCs could result from 
  exclusive presentation of exogenous antigens on MHC II, 
but not MHC I, molecules. As suggested earlier (  17  ), PDCs 
might lack the phagosome-to-cytosol pathway required for 
cross-presentation. Importantly, this would spare the priming 
PDCs from a unique negative-feedback mechanism through 
in the LNs. Importantly, PDCs diff  ered from cDCs in that they 
could not induce CD8     T cell priming. 
  Naive T cells are stimulated in lymphoid organs by spe-
cialized,   “  professional  ”   APCs that induce clonal T cell ex-
pansion and diff  erentiation. Effi   cient eradication of invading 
microbes requires distinct immune responses, involving both 
cellular and humoral defense mechanisms. Pathogen identifi  -
cation is believed to result from engagement of pathogen 
sensors (such as TLRs), which are diff  erentially expressed on 
APCs and may allow distinct APC subsets to trigger specifi  c 
responses. Division of labor between APCs, however, re-
mains poorly understood. This is particularly true for IPC/
PDCs, which are critical for NK cells and cDC function, but 
whose in vivo capacity for antigen presentation and T cell 
priming remains unclear. We reasoned that any potential 
APC functions of PDCs might be masked by the presence of 
cDCs, and thus decided to test naive T cell responses in mice 
that were conditionally depleted of cDCs. 
  Figure 8.     In vivo antigen targeting of PDCs leads to LN PDC-mediated 
in vitro CD4     T cell proliferation. CD11c  high   cDCs, PDCs, and B cells 
were sorted from spleens and LNs of BALB/c mice that were i.v. or s.c. 
immunized with OVA or mPDCA-1  –  F(ab  ’  )  2    –  OVA, and cultured with OVA-
specifi  c CD4     T cells (DO11.10) for 72 h, after which thymidine incorpora-
tion was measured. Results are plotted as the arithmetic mean of cycles 
per minute (cpm) from triplicate cultures with cells isolated from immunized 
mice minus the mean cpm of cultures of the respective cell populations 
isolated from unimmunized mice. The absolute mean cpm for the LN 
cells were as follows: 4,297 (cDC/OVA); 30,537 (LNPDC/OVA); 5,065 (LNPDC 
mPDCA-1  –  OVA); and 2,995 for spleen cells (cDC/OVA). The positive frac-
tion of PDCs contained   <  0.01% contaminating CD11c  high   cDCs.   n   = 4 for 
each group. Error bars represent the SD. Controls include responder T cells 
only and T cells with B cells isolated from PDCA-OVA immunized mice.     JEM VOL. 204, August 6, 2007 
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F(ab  ’  )  2   fragments were conjugated to OVA (Sigma-Aldrich) activated with 
succinimidyl 4-(  N  -maleimidomethyl) cyclohexane-1-carboxylate (Pierce 
Chemical Co.) according to the manufacturer  ’  s protocol. F(ab  ’  )  2  -OVA con-
jugates were size fractionated and sterile fi  ltrated (Millex GV fi  lter unit 0.22 
  μ  m; Millipore) for in vivo application. Construct integrity was evaluated by 
Western blot analysis with horseradish peroxidase  –  conjugated polyclonal 
rabbit anti  –  rat Ig (H+L; Jackson ImmunoResearch Laboratories) and horse-
radish peroxidase  –  coupled rabbit anti-OVA antibody (Research Diagnostics, 
Inc.), respectively. OVA content was determined by ELISA to be     75 ng 
OVA/    g mPDCA-1 F(ab  ’  )  2  -OVA conjugate. To demonstrate in vivo spec-
ifi  city, we injected 10  –  25   μ  g FITC-conjugated anti  –  mPDCA-1  –  F(ab  ’  )  2    –
  OVA i.v. or into the hind footpads. 3 h later, spleens or pooled popliteal and 
inguinal LNs were analyzed for PDC-specifi  c targeting. 
  Immunohistochemistry.     4-    m paraffi   n sections of popliteal LNs were 
deparaffi   nized and treated with 2 ml HCl, H  2  O  2   in 50% methanol, and 50% 
PBS for 15 min at room temperature. For antigen exposure, sections were 
microwaved in 10 mM sodium citrate, pH 6.0. After blocking with 20% heat-
inactivated normal goat serum and 0.1% Triton X-100 in PBS, sections were 
incubated overnight at room temperature with polyclonal biotinylated goat 
anti-GFP antibody (ab6658; Abcam). Staining was revealed with an avidin  –
  biotin peroxidase complex (Vectastain Elite ABC kit; Vector Laboratories). 
Finally, the sections were stained with hematoxylin-Mayer (Finkelman). 
  Analysis of T cell proliferation.     TCR transgenic T cells were isolated 
from spleens and LNs of respective mice, enriched by MACS cell sorting 
with anti-CD8 or -CD4 antibodies according to the manufacturer  ’  s protocol 
(Miltenyi Biotec GmbH), and labeled with CFSE (C-1157; Invitrogen) (  57  ). 
CFSE-labeled T cells (1  –  2   ×   10  6  /mouse) were injected into the tail veins of 
the recipient mice. 
  Immunization.     Mice were immunized with cell-associated antigen by i.v. 
injection of 3   ×   10  7   OVA-loaded     2m    −  /  −    splenocytes (  37  ). Soluble OVA 
(Sigma-Aldrich) was injected i.v. (10     g/mouse) or s.c. into hind footpads 
(10     g/footpad). KLH (Sigma-Aldrich) was injected s.c. into hind footpads 
(10     g/footpad). The anti  –  DEC205-OVA conjugate (provided by K. Mahnke, 
University Hospital Heidelberg, Heidelberg, Germany) was used at a dose of 
7 ng/footpad. F(ab  ’  )  2   and anti  –  mPDCA-1  –  F(ab  ’  )  2    –  OVA were injected 
at a dose of 8     g/footpad. For measurement of Ag uptake, mice were 
immunized with DQ-OVA (Invitrogen) by hind footpad injection of 
10     g/footpad. 
  Intracellular cytokine staining.     Mice were immunized with 25     g OVA 
in 5 nmol/footpad CpG nucleotide 1668 (TIB MOLBIOL). 2 d later, mice 
were in vivo restimulated by intravenous injection of 100     g OVA peptide 
(residues 323  –  329) 2 h before the removal of popliteal LNs. The tissue was 
minced and incubated in 1 mg/ml of collagenase D (Roche) for 20 min at 
37  °  C in medium supplemented with 10     g/ml brefeldin A (Calbiochem). 
Cells were fi  xed in 2% formaldehyde, permeabilized with 0.3% saponin, and 
stained for anti-CD45.1, -CD4, and   –  IFN-  	   antibodies. 
  Flow cytometric analysis.     The staining reagents used in this study in-
cluded the PE-coupled anti-CD4, CD19, CD45.1, CD11c, CD45RB, CD8, 
and KJ126 (DO11.10 clonotype); biotinylated anti-CD45.1 and mPDCA-1; 
APC-coupled CD11c, CD4, IFN-  	  , and CD8; the FITC-coupled anti-CD4; 
PE-Cy5.5  –  coupled anti-B220 (Caltag Laboratories); and PerCP-coupled 
anti-CD4 and CD8 antibodies. Unless otherwise indicated, the reagents were 
obtained from PharMingen or eBioscience. The anti–Siglec-H antibody (440c) 
was provided by M. Colonna (Washington University School of Medicine, 
St. Louis, MO). Cells were analyzed on a cytometer (FACSCalibur; BD 
Biosciences) using CellQuest software (BD Biosciences). 
  Online supplemental material.     Fig. S1 provides additional fl  ow cytomet-
ric and histological data concerning the DTx sensitivity and resistance of 
cDCs and PDCs, respectively. Figs. S2 and S3 show unimpaired PDC-driven 
which CTLs kill APCs, and thereby terminate the priming 
process (  67, 68  ). The inability to cross-present would render 
PDCs resistant to the CTLs elicited by cDCs. In the course 
of an ongoing response to a given antigen, the APC balance 
might therefore be shifted from cDCs to PDCs and, as a result, 
priming of CD4     T cells and potentially humoral responses 
might be favored. As CD4     T cells also critically contribute 
to the development of CD8     T cell memory (  69  ), the APC 
function of PDCs might have a general impact on the shape 
of immune responses. 
  We show that in LNs, PDCs effi   ciently trigger produc-
tive naive CD4     T cell responses. Interestingly, and in con-
trast to cDC-triggered responses, PDC-triggered CD4     T cell 
responses are not associated with concomitant CD8     T cell 
expansion. Instead, PDCs initiate unique CD4     Th cell  –
  dominated primary immune responses. 
    MATERIALS AND METHODS   
  Mice.     CD11c-DTR transgenic (B6.FVB-Tg Itgax-DTR/GFP 57Lan/J) 
mice (  12  ); OT-I (C57BL/6) TCR transgenic mice harboring OVA-specifi  c 
CD8     T cells (  42  ); DO11.10 (BALB/c); and OT-II (C57BL/6) TCR trans-
genic mice harboring OVA-specifi  c CD4     T cells (  35  ); B cell  –  defi  cient mice 
(C57BL/10-  IgH-6tm1Cgn (      Mt) (  48  ) and LanDTR mice carrying the 
DTR-GFP gene under the Langerin promoter ( 50  ). LanDTR:CD11cDTR 
and DTRtg:    MT mice were obtained by intercrossing of the respective 
lines. Mixed (DTR   >   WT) BM chimeras were generated as previously 
reported (  57  ). For systemic cDC depletion, mice were injected i.p. with 
4 ng/g body weight DTx (D-2918; Sigma-Aldrich). For local cDC deple-
tion in popliteal LNs, animals were injected with 20 ng DTx s.c. into hind 
footpads. If indicated, DTx was applied. All mice were used at the age of 
6  –  12 wk, maintained under specifi  c pathogen-free conditions, and han-
dled according to protocols approved by the Weizmann Institute Animal 
Care Committee as per international guidelines. 
  Isolation of CD11c  high   DCs and PDCs.     Peripheral LNs or spleens 
were digested with 1 mg/ml of collagenase D (Roche) for 45 min at 
37  °  C. Tissues were mechanically disrupted in PBS, and for spleens, RBC 
lysis was performed by incubation with 1 ml ACK buff  er (0.15 M NH  4  Cl, 
0.1 M KHCO  3  , 1 mM EDTA, and PBS) for 1 min at room temperature. 
PDCs were enriched by MACS cell sorting according to the manufacturer  ’  s 
protocol (Miltenyi Biotec GmbH). 
  In vitro proliferation assay.     BALB/c mice were immunized i.v. (20     g 
OVA or 10     g mPDCA-1  –  OVA) and s.c. into hind footpads (10     g OVA 
or mPDCA-1  –  OVA). 24 h later, spleens and popliteal and inguinal LNs 
were harvested, and cDCs and PDCs were purifi  ed by high-speed cell 
sorting according to CD11c and mPDCA-1 expression using a FACS Aria 
(Becton-Dickinson). Positive fraction of PDCs contained   <  0.01% con-
taminating CD11c  high   cDCs. DCs (10  4  ) or PDCs (2  –  3   ×   10  4  ) were cul-
tured with 10  5   DO11.10 CD4  +   T cells. Cultures were pulsed after 72 h 
with 1     Ci of [H  3  ]thymidine, and incorporation was measured 16 h later. 
  IFN-     secretion assay.     MACS-enriched splenic PDCs were cultured at 
2   ×   10  6   cells/ml in complete RPMI 1640 for 20 h, with 400 HAU/ml in-
fl  uenza virus A/Texas/1/77 (provided by R. Arnon, The Weizmann Institute, 
Rehovot, Israel). Supernatants were assayed using an IFN-     ELISA kit (Per-
formance Biomedical Laboratories). 
  Conjugation of OVA to anti  –  mPDCA-1 F(ab  ’  )  2   fragments and 
specifi  city test.     Anti  –  mPDCA-1 monoclonal antibody (rat IgG2b,   
  ; Milt-
enyi Biotec GmbH) was digested with Pepsin A (Sigma-Aldrich). After size 
fractionation (Superdex 200 16/60 gel fi  ltration column; GE Healthcare), 1932 LN PDC PRIME CD4 T CELLS | Sapoznikov et al.
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